Abivax SA Sponsored ADR

ABVX Healthcare Biotechnology

EPS
−98.8%
Free cash flow
−48.3%
Total debt
−98.5%

Quarter to June 2026, against a year earlier

85.78 1.60 +1.90%
Market cap
$7.4B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Abivax SA Sponsored ADR (ABVX) EPS (diluted)

Alert me on EPS (diluted)

Abivax SA Sponsored ADR's EPS (diluted) for fiscal 2025 was −$5.46, compared with −$3.03 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$6.06. Over the past ten years it has ranged from −$5.46 (fiscal 2025) to −$1.83 (fiscal 2018) — the current reading is the lowest in ten years. Abivax SA Sponsored ADR ranks 463rd of 580 Biotechnology companies by EPS (diluted).

EPS (diluted), annual

Embed this chart

Annual newest first

Period EPS (diluted) Change
FY2025 −$5.46 —
FY2024 −$3.03 —
FY2023 −$3.71 —
FY2022 −$3.35 —
FY2021 −$2.92 —
FY2020 −$2.99 —
FY2019 −$2.81 —
FY2018 −$1.83 —

Quarterly newest first

Period EPS (diluted) Change
Jun 2026 −$1.71 —
Mar 2026 −$0.71 —
Dec 2025 −$1.19 —
Sep 2025 −$2.45 —
6 more quarters

Against its own ten years

Low −$5.46 High −$1.83
Ten-year median −$3.01
Current reading's percentile 13

EPS (diluted) against peers

What EPS (diluted) is

Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.

Reported line item

The full definition of EPS (diluted) →

More on ABVX